- Home
- HYPR vs CTSO Comparison
HYPR vs CTSO Comparison
Compare HYPR & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYPR
- CTSO
- Stock Information
- Founded
- HYPR 2014
- CTSO 1997
- Country
- HYPR United States
- CTSO United States
- Employees
- HYPR N/A
- CTSO N/A
- Industry
- HYPR Medical Specialities
- CTSO Medical/Dental Instruments
- Sector
- HYPR Health Care
- CTSO Health Care
- Exchange
- HYPR Nasdaq
- CTSO Nasdaq
- Market Cap
- HYPR 54.6M
- CTSO 61.3M
- IPO Year
- HYPR N/A
- CTSO N/A
- Fundamental
- Price
- HYPR $0.77
- CTSO $1.07
- Analyst Decision
- HYPR Strong Buy
- CTSO Strong Buy
- Analyst Count
- HYPR 3
- CTSO 3
- Target Price
- HYPR $1.33
- CTSO $4.67
- AVG Volume (30 Days)
- HYPR 329.2K
- CTSO 68.3K
- Earning Date
- HYPR 05-12-2025
- CTSO 05-08-2025
- Dividend Yield
- HYPR N/A
- CTSO N/A
- EPS Growth
- HYPR N/A
- CTSO N/A
- EPS
- HYPR N/A
- CTSO N/A
- Revenue
- HYPR $12,890,000.00
- CTSO $35,594,520.00
- Revenue This Year
- HYPR $24.00
- CTSO $18.72
- Revenue Next Year
- HYPR $28.70
- CTSO $19.75
- P/E Ratio
- HYPR N/A
- CTSO N/A
- Revenue Growth
- HYPR 16.84
- CTSO 14.51
- 52 Week Low
- HYPR $0.58
- CTSO $0.70
- 52 Week High
- HYPR $1.90
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- HYPR 50.65
- CTSO 56.95
- Support Level
- HYPR $0.58
- CTSO $0.97
- Resistance Level
- HYPR $0.76
- CTSO $1.14
- Average True Range (ATR)
- HYPR 0.06
- CTSO 0.07
- MACD
- HYPR 0.02
- CTSO 0.02
- Stochastic Oscillator
- HYPR 95.70
- CTSO 66.67
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.